Last update June 12, 2018


Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Antiandrogenic drug that acts by blocking testosterone receptors which is used for treatment of prostate carcinoma.
Not authorized for use in women although it is used for treatment of hirsutism with same or greater efficacy than Spironolactone (Erenus 1994 Cusan 1994, Moghetti 2000), androgenetic alopecia (Paradisi 2011). Also used for treatment of Polycystic Ovary Syndrome (Gambineri 2006).

At latest update no published data on excretion into breast milk were found.
Its high plasma protein-binding capacity makes it unlikely the excretion of significant amounts into breastmilk.

Not alterations on prolactin level have been reported.

Be aware that an aniline-containing metabolite would appear, which can lead under certain circumstances to develop Methemoglobinemia.

A known and safer alternative should be preferred until more published data on this drug related to breastfeeding is available within the first 6 mo after birth, especially during the neonatal period and in case prematurity.
Exposure through breastmilk may be minimized by waiting at least 6 hours before resuming breastfeed after the last dose of drug.


  • Spironolactone (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Flutamide in other languages or writings:


Flutamide belongs to this group or family:


Main tradenames from several countries containing Flutamide in its composition:


Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 276 daltons
Protein Binding 92 - 96 %
Tmax 1 - 2 hours
4.7 - 6 hours


  1. FDA. Flutamide. Drug Summary. 2014 Full text (in our servers)
  2. Paparodis R, Dunaif A. The Hirsute woman: challenges in evaluation and management. Endocr Pract. 2011 Abstract
  3. Paradisi R, Porcu E, Fabbri R, Seracchioli R, Battaglia C, Venturoli S. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss. Ann Pharmacother. 2011 Abstract
  4. Unluhizarci K, Ozel D, Tanriverdi F, Karaca Z, Kelestimur F. A comparison between finasteride, flutamide, and finasteride plus flutamide combination in the treatment of hirsutism. J Endocrinol Invest. 2009 Abstract
  5. Dikensoy E, Balat O, Pence S, Akcali C, Cicek H. The risk of hepatotoxicity during long-term and low-dose flutamide treatment in hirsutism. Arch Gynecol Obstet. 2009 Abstract
  6. Calaf J, López E, Millet A, Alcañiz J, Fortuny A, Vidal O, Callejo J, Escobar-Jiménez F, Torres E, Espinós JJ; Spanish Working Group for Hirsutism. Long-term efficacy and tolerability of flutamide combined with oral contraception in moderate to severe hirsutism: a 12-month, double-blind, parallel clinical trial. J Clin Endocrinol Metab. 2007 Abstract
  7. Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab. 2006 Oct;91(10):3970-80. Epub 2006 Jul 25. Abstract
  8. Taner C, Inal M, Başogul O, Onoglu A, Karanfil C, Tinar S, Ispahi C. Comparison of the clinical efficacy and safety of flutamide versus flutamide plus an oral contraceptive in the treatment of hirsutism. Gynecol Obstet Invest. 2002 Abstract
  9. AEMPS. Flutamida. Ficha técnica. 2001 Full text (in our servers)
  10. Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000 Abstract
  11. Müderris II, Bayram F. Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. J Endocrinol Invest. 1999 Abstract
  12. Rittmaster RS. Hirsutism. Lancet. 1997 Abstract
  13. Erenus M, Gürbüz O, Durmuşoğlu F, Demirçay Z, Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil Steril. 1994 Abstract
  14. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril. 1994 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM